The generic-drug industry and the FDA have agreed to a three-tier system of review goals for ANDA amendments under the new generic-drug user fee program now under negotiation. Review goals would vary depending on the number and type of amendments companies file, according to minutes from a recent meeting to establish the program.
Generic Line